Open-label study to assess efficacy (diagnostic performance) and safety of a single dose (i.v.) of NMK36 in patients with clinically- suspected glioma

Trial Profile

Open-label study to assess efficacy (diagnostic performance) and safety of a single dose (i.v.) of NMK36 in patients with clinically- suspected glioma

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Nihon Medi-Physics
  • Most Recent Events

    • 17 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 16 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top